Navigation Links
Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
Date:11/13/2008

nologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Alseres, Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

Contact: Sharon Correia - 508-497-2360 ext. 224

Alseres Pharmaceuticals, Inc.

scorreia@alseres.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Alseres Pharmaceuticals, Inc. Raises $5 Million
2. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
3. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
4. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
5. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
6. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
7. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
8. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
9. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
10. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
11. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies Corp. ... developing first in class collagenase-based products marketed as ... in the U.S. and XIAPEX ® in ... from a randomized, double-blind Phase 2a study of ... edematous fibrosclerotic panniculopathy. The results showed that all ...
(Date:8/21/2014)... DESY scientists has observed tiny quantum vortices in cold ... journal Science that the exotic vortices arrange ... is the first time that the quantum vortices, which ... is known as superfluid helium, have been detected in ... Andrey Vilesov of the University of Southern California, one ...
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the Netherlands ... His Majesty Willem-Alexander, King of the Netherlands, has announced ... POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant in ... will take part in the Grand Opening Ceremony to ... p.m. and tour the plant. POET-DSM is a joint ...
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... MILWAUKEE--- GE Healthcare , a $10 billion provider ... information technology, announced today that it has received ... healthcare industry authority, KLAS Enterprises for the second ... called Centricity(R) Pharmacy Information System, was recognized in ...
... OASYS , a leading developer of K-12 software ... Behind management, recently announced their online, ASP software ... (IEPs) and monitors the progress of children with ... in 16 Wisconsin school districts during 2003, provides ...
... Third Wave Technologies Inc , a maker of molecular ... 2D6 analysis panel, which provides clinical trial laboratories with ... for the important 2D6 gene. , ,The panel is ... the ability to configure custom assay panels. The panel ...
Cached Biology Technology:Third Wave Releases Gene Test 2
(Date:8/21/2014)... An international team of scientists including researchers from the University ... commonly known as canolain the journal Science . Their ... which is used widely in farming and industry. , ... Europe, but the winter crop is increasingly cultivated in Georgia. ... low levels of saturated fat and rich supply of omega-3 ...
(Date:8/21/2014)... Conn. , Aug. 21, 2014 Nxt-ID, ... the growing mobile commerce market, announced today that its ... common stock to be issued in its proposed underwritten ... approved for listing on The Nasdaq Capital Market, subject ... the common stock and warrants, and will trade under ...
(Date:8/21/2014)... and other itchy, flaky maladies in humans has now ... reefs and the extreme environments of arctic soils and ... journal PLOS Pathogens considers the diversity, ecology, ... Malassezia in light of new insights gained from ... University of Hawai,i at Mānoa scientist Anthony Amend discovered ...
Breaking Biology News(10 mins):Canola genome sequence reveals evolutionary 'love triangle' 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... to grow iron-oxidizing bacteria using electricity instead of iron, an ... and could one day be used to turn electricity into ... mBio , the online open-access journal of the American ... supplies these bacteria with a steady supply of electrons that ...
... LIVERMORE, CALIF. A new way of looking at ... in the cell membrane, changing the understanding of its ... from Lawrence Livermore National Laboratory, the University of Illinois ... relationships among molecules within cell membranes. Their ...
... release is available in German . ... nervous system has an astonishing capacity for regeneration following ... Medicine in Gttingen have discovered that, following nerve damage, ... makes an important contribution to the regeneration of damaged ...
Cached Biology News:Scientists trick iron-eating bacteria into breathing electrons instead 2New look at cell membrane reveals surprising organization 2New look at cell membrane reveals surprising organization 3Glial cells assist in the repair of injured nerves 2